phrykt

Inhibrx Biosciences, Inc. (INBX): who owns it and who trades it

As of Nov 16, 2026, INBX insiders reported 5 open-market sales worth $279K and 19 purchases worth $6.3M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kimberly Manhard (Director), with $279K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Inhibrx Biosciences

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns INBX

162 funds and institutions reported INBX shares worth $1.4B at the end of Q2 2026, about 98% of the company. The largest holder is Morgan Stanley with 9.0%.

Funds and institutions (13F) 98%Everyone else 2%

10 largest owners, by share of the company

Morgan Stanley9.0%
Perceptive Advisors LLC8.9%
Sanofi7.9%
Viking Global Investors LP7.7%
HighTower Advisors, LLC6.0%
Bank of America Corp5.8%
BlackRock, Inc.5.7%
Schonfeld Strategic Advisors LLC4.8%
State Street Corp4.4%
Vanguard Capital Management LLC3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Morgan Stanley1.31M8.95%$124M+4%
Perceptive Advisors LLC1.30M8.88%$123M-10%
Sanofi1.16M7.93%$110MNo change
Viking Global Investors LP1.12M7.69%$106M-22%
HighTower Advisors, LLC870,5515.96%$82.5MNo change
Bank of America Corp841,1415.76%$79.7M+2474%
BlackRock, Inc.825,9725.65%$78.3M+3%
Schonfeld Strategic Advisors LLC697,5864.78%$66.1M+174%
State Street Corp640,4584.38%$60.7M+16%
Vanguard Capital Management LLC492,4773.37%$46.7M+1%
Woodline Partners LP400,8922.74%$38M+4%
Capital Research Global Investors363,0502.49%$34.4M-8%
Goldman Sachs Group Inc338,1762.32%$32M+256%
PFM Health Sciences, LP308,3852.11%$29.2M+1%
Sofinnova Investments, Inc.303,1032.08%$28.7M-25%
Healthcare of Ontario Pension Plan Trust Fund271,7001.86%$25.7M+59%
Parkman Healthcare Partners LLC256,9501.76%$24.3M–
Geode Capital Management, LLC256,1751.75%$24.3M+11%
First Turn Management, LLC164,7831.13%$15.6M–
Millennium Management LLC147,2001.01%$13.9M-55%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, INBX insiders reported $6.3M of open-market purchases and $279K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$6.3M
19 trades, 3 people
Sales, 12 months
$279K
5 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 14, 2026
Filed Oct 14, 2026

Purchases and sales by month

$5.5M$5.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 14, 2026Mark LappeCEOPurchase2,470$84.07$208KForm 4
Oct 14, 2026Mark LappeCEOPurchase2,470$85.00$210KForm 4
Oct 14, 2026Mark LappeCEOPurchase100$85.76$8.6KForm 4
Oct 14, 2026Mark LappeCEOPurchase2,449$84.07$206KForm 4
Oct 14, 2026Mark LappeCEOPurchase2,451$85.00$208KForm 4
Sep 28, 2026Mark LappeCEOPurchase1,500$98.88$148KForm 4
Sep 28, 2026Mark LappeCEOPurchase3,000$101.70$305KForm 4
Sep 25, 2026Mark LappeCEOPurchase3,324$98.87$329KForm 4
Sep 25, 2026Mark LappeCEOPurchase2,176$99.60$217KForm 4
Sep 23, 2026Jon Faiz KayyemDirectorPurchase5,000$100.00$500KForm 4
Sep 16, 2026Jon Faiz KayyemDirectorPurchase5,000$100.00$500KForm 4
Sep 15, 2026Kimberly ManhardDirectorSale500$105.05$52.5KForm 4
Sep 14, 2026Kimberly ManhardDirectorSale500$110.26$55.1KForm 4
Sep 11, 2026Kimberly ManhardDirectorSale500$111.78$55.9KForm 4
Sep 9, 2026Kimberly ManhardDirectorSale500$115.80$57.9KForm 4
Sep 8, 2026Kimberly ManhardDirectorSale500$115.14$57.6KForm 4
Sep 8, 2026Jon Faiz KayyemDirectorPurchase5,000$113.52$568KForm 4
Sep 8, 2026Douglas ForsythDirectorPurchase2,500$114.65$287KForm 4
Sep 8, 2026Mark LappeCEOPurchase500$108.24$54.1KForm 4
Sep 8, 2026Mark LappeCEOPurchase9,681$112.28$1.1MForm 4
Sep 8, 2026Mark LappeCEOPurchase1,219$111.88$136KForm 4
Sep 8, 2026Mark LappeCEOPurchase5,895$99.29$585KForm 4
Sep 8, 2026Mark LappeCEOPurchase6,605$100.64$665KForm 4
Sep 8, 2026Mark LappeCEOPurchase1,100$107.12$118KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark LappeChief Executive Officer, Director$4.5M–Oct 14, 2026
Jon Faiz KayyemDirector$1.6M–Sep 23, 2026
Douglas ForsythDirector$287K–Sep 8, 2026
Kimberly ManhardDirector–$279KSep 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INBX short interest

Very high short interest. 23.0% of INBX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 16%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.39M INBX shares were sold short, 23.0% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 339,064 shares, buying them all back would take about 10.0 trading days (days to cover).

Shares short, % of all shares

23.0%May 15Oct 3024.1%

Days to cover

10.0May 15Oct 3018.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.39M23.03%-1%339,06410.0
Oct 15, 20263.42M23.22%-0%202,98416.8
Sep 30, 20263.43M23.32%+1%290,35911.8
Sep 15, 20263.39M23.06%+3%408,4808.3
Aug 31, 20263.30M22.41%+3%317,49610.4
Aug 14, 20263.22M21.85%-4%223,49014.4
Jul 31, 20263.34M22.87%-3%213,59415.6
Jul 15, 20263.43M23.51%-0%379,8739.0
Jun 30, 20263.45M23.60%+4%347,7139.9
Jun 15, 20263.30M22.59%+4%321,93010.2
May 29, 20263.18M21.77%+8%341,2529.3
May 15, 20262.93M20.08%+7%654,2414.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Inhibrx Biosciences company events

Inhibrx Biosciences filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 28, 2026.

  1. Sep 28, 2026AnnouncementShared information with investors. Filing
  2. Sep 8, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for… Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jul 16, 2026AgreementInhibrx Biosciences, Inc., Oxford Finance LLC as collateral agent, and the other lenders party thereto, entered into a second amendment to the Loan and Security Agreement dated as of January 13, 2025, as amended by the First Amendment dated March 18, 2026, pursuant to which the Lenders expanded the… Filing
  5. Jun 15, 2026AnnouncementThe Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. Filing
  6. Jun 3, 2026VoteReported shareholder vote results. Filing
  7. May 14, 2026ResultsReleased financial results. Filing
  8. May 11, 2026AnnouncementInhibrx posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. Filing
  9. Apr 21, 2026AnnouncementInhibrx posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. Filing
  10. Mar 19, 2026ResultsReleased financial results. Filing
  11. Feb 23, 2026AnnouncementShared information with investors. Filing
  12. Dec 16, 2025AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Inhibrx Biosciences financials

Famous investors that hold INBX

5 of the 50 well-known investors we track reported holding INBX in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $111M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20261.11M$111M0.3%-1%
Ken Griffin · Citadel AdvisorsQ3 202622,855$2.3M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202616,673$1.7M0.0%-36%
Israel Englander · Millennium ManagementQ3 202610,642$1.1M0.0%-93%
Paul Tudor Jones · Tudor Investment CorpQ3 20268,542$855K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named INBX in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Schonfeld Strategic Advisors LLC13G/A6.5%
Nov 13, 2026Schonfeld Strategic Advisors LLC13G/A6.5%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A2.4%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A2.4%

Questions about Inhibrx Biosciences, Inc. (INBX) stock

Who owns the most INBX stock?

The largest reported owner of Inhibrx Biosciences, Inc. (INBX) is Morgan Stanley, with 9.0% of the company. In total, 162 funds and institutions reported holding INBX at the end of Q2 2026, together about 98% of the shares. See the largest owners.

Are INBX insiders buying or selling?

In the last 12 months, INBX insiders reported 19 open-market purchases worth $6.3M and 5 sales worth $279K. The latest trade was on Oct 14, 2026. See every trade.

What is the short interest in INBX?

As of Oct 30, 2026, 3.39M INBX shares were sold short, 23.0% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 339,064 shares, buying them all back would take about 10.0 trading days (days to cover). See the history.

Which famous investors hold INBX?

5 of the 50 well-known investors we track reported INBX in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Steve Cohen. The largest position is worth $111M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.